Please note some content on this site is no longer supported on Internet Explorer 8, we recommend you upgrade your browser
Targovax is developing two complementary and highly targeted approaches to cancer immunotherapy: a peptide-based targeted immunotherapy platform for patients with RAS-mutated cancers and a virus-based oncolytic immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors.
Both treatment approaches harness the patient’s own immune system to fight the cancer.
Read more about Virus-based Immunotherapy (ONCOS-102)
Read more about Peptide-based Immunotherapy (TG01)
Targovax brings together two unique & complementary immuno-oncology technologies
Investor Email Alerts